

CO-CREATING CANADIAN RARE FALL CONFERENCE 2025

NOVEMBER 25 - 26, 2025 OTTAWA MARRIOTT HOTEL

This agenda outlines the full schedule of sessions, speakers, and activities planned for "Co-Creating Canadian Rare" Fall Conference 2025, We look forward to a dynamic program focused on learning, networking & innovation.

Day 1: Up Close and Personal with Rare

Tuesday, November 25, 2025

7:00 AM - 9:00 AM Rare Champions' Breakfast: Parliamentarians,

Patients, and Professionals (by invitation only)

9:30 AM - 10:30 AM Rare Press Briefing (by invitation only)

10:30 AM - 11:00 AM Conference Registration (Victoria Ballroom)

11:00 AM - 12:00 PM Rare Experiences Canada 2025 (Balcony,

Victoria Ballroom)

12:00 fghjkl Lunch

CCXCPM - 1:00 PM

C vc Conference Opens

Opening Plenary: Canada Does Rare

Durhane Wong-Rieger, CORD; Jida El Hajjar, Loeys-

Dietz Syndrome Foundation Canada

1:30 PM – 3:00 PM How Canada's Rare Disease Drug Strategy

Impacts Access

RDDS: Evaluation Framework Indicators of

Impact Daniel McDonald, Health Canada; Sophie Sommerer, Biologics & Gene Therapies Directorate, François Bernier, Canadian Rare Disease Network, Thierry Lacaze, RareKids Can

RDDS: Impact on Patient Access Sang Mi Lee, Morse Consulting

RDDS: Demonstrating Patient Impact Maryam Soleimani, BC Cancer (virtual)

RDDS: Leveraging Outcomes-Based Agreements Rebeccah Marsh, IHE

3:00 PM - 3:15 PM **Break**

3:15 PM - 3:45 PM Panel: Right Pricing Rare Drugs for Timely, Affordable and Sustainable Access

PMPRB Guidelines Update: Guillaume Couillard

pCPA Update: Mauro Chies, pCPA

Working Groups: Improving Access and Working Group 1 Demonstrating Impact

> **Using OBA Playbook to Improve Access** Leads: Rebeccah Marsh & Sara Ethier

 Assessing Impact of RD Drug Strategy **Common List**

Leads: Alison Oliver & Krysta Davies Foss

 Learnings from Rare Disease Drug Strategy 1.0 and Aspirations for RDDS 2.0

Leads: Graham Statt & Wayne Critchley

 Mind the Gaps from Regulator to Payer Leads: Sylvie Bouchard & Jida El Hajjar

3:45 PM - 4:30 PM

4:30 PM - 5:00 PM Workshop Feedback and Reflections Panel:

Graham Statt, Sang Mi Lee, Rebeccah Marsh, Sylvie Bouchard, J & J (TBD); Roche (TBD); Sara Ethier, CORD; Lisa McCoy, CORD; Alison Oliver, Innomar Strategies

5:30 PM - 8:00 PM Networking Reception*

Summit (29th floor) *All conference participants are invited to attend.

Day 2: From Ideas to Action

Wednesday, November 26, 2025

8:30 AM - 9:00 AM Breakfast (Victoria Ballroom)

9:00 AM - 9:05 AM Day 1 Recap Durhane Wong-Rieger

9:05 AM - 9:15 AM Investing in Canada's Rare Future Karen Helm,
Alexion

9:15 AM - 10:15 AM Expert Panel: Canadian Solutions Improving
Patient Journey

- Think Rare: From Undiagnosed to Clinical
 Care Kym Boycott, Children's Hospital of Eastern
 Ontario
- For the Cost of One Drug Vial Case for SMA
 Multidisciplinary Clinic Aaron Izenberg,
 Sunnybrook HSC
- Ste Justine Centre of Expertise for Complement-Mediated Rare Diseases

Alexandra Cambier and Anne-Laure Lapeyraque, CHU Ste Justine ZebraCARE: When and Where Needed Katrina Fontaine

10:15 AM - 10:45 AM

Panel: Social and Economic Impacts of Living with Rare Condition

- 2025 Canadian Survey of Patients and Families:
 Deborah Marshall, University of Calgary
- Impacts of Delayed Diagnosis and Treatment:
 Gina Cioffi, Chiesi USA

10:45 AM - 11:00 AM

Break

11:00 AM - 11:30 PM

Panel:

- aTTP: New Evidence, New Hope: Mina Raja
- Fredreich's Ataxia: When Assessors Disagree:
 François Theberge
- Rett Syndrome: Standardizing Heterogeneity:
 Sabrina Millson
- C3G: Targeting Rare Kidney Conditions, Aaren Jauhal, UHN

11:30 AM - 12:30 PM

Working Groups: Optimizing Patient Journey

Working Group 2

- Transitioning Kids to Adults and Beyond:
 Leads: Aaron Izenberg & Susi Vander Wyk
- Value of Preventing Crises: FOP and FCS
 Leads: Jida El Hajjar & François Theberge
- Hiding in Plain Sight: Strategies for Finding,
 Diagnosis, and Treating

Leads: Kym Boycott & Lindsay Williamson

 Making the Case for Care Leads: Karen Kelm & Katrina Fontaine

12:30 PM - 1:30 PM

Lunch

1:30 PM - 2:00 PM Working Group Feedback

2:00 PM - 2:45 PM Feedback and Reflections Panel:

Panelists: Risini Weeratna, National Research Council; François Bernier, CRDN; Sophie Sommerer, DG BGTD; Thierry Lacaze, RareKids-CAN; John Snowden, Amgen; Pfizer (TBD); Alice Williams,

CORD

2:45 PM - 3:00 PM Next Steps: Recommendations for Canada's Rare

Disease (Drug) Strategy 2.0

All